lung cancer patients and pulmonary embolism risk factors Overview Pulmonary embolism (PE) is a grave complication observed in individuals afflicted with lung cancer. This investigation aimed to ascertain the risk factors and evaluate the clinical attributes of advanced lung cancer patients who develop PE. In this research, a retrospective assessment was conducted on
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients Overview In the Phase 3 trial RATIONALE-303 (NCT03358875), the study evaluated the health-related quality of life (HRQoL) among patients with advanced non-small cell lung cancer (NSCLC) who were treated with either tislelizumab or docetaxel. The assessment utilized three measurement instruments: EORTC QLQ-C30,
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
Anlotinib with Camrelizumab in Lung Cancer Treatment Background Checkpoint inhibitors (CPIs) and anti-angiogenic agents are emerging as potential novel treatment choices for advanced cancers including metastatic non-small-cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.
Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%